



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

BMS-688521

Cat. No.:	HY-10596
CAS No.:	893397-44-9
Molecular Formula:	C ₂₆ H ₁₉ Cl ₂ N ₅ O ₄
Molecular Weight:	536.37
Target:	Integrin
Pathway:	Cytoskeleton
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (186.44 mM; Need ultrasonic)				
	Preparing Stock Solutions	Solvent Concentration Mass	1 mg	5 mg	10 mg
		1 mM	1.8644 mL	9.3219 mL	18.6438 mL
		5 mM	0.3729 mL	1.8644 mL	3.7288 mL
		10 mM	0.1864 mL	0.9322 mL	1.8644 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 5 mg/mL (9.32 mM); Suspended solution; Need ultrasonic				
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 5 mg/mL (9.32 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	BMS-688521 is a highly potent, orally active inhibitor of the LFA-1/ICAM interaction, with an IC ₅₀ of 2.5 nM in the adhesion assay and an IC ₅₀ of 60 nM in the MLR assay. BMS-688521 is efficacious in a mouse allergic eosinophilic lung inflammation model ^[1] .
In Vitro	BMS-688521 in a mouse specific adhesion assay employed mouse splenocytes and a mouse ICAM-1 expression cell line, b.END3. BMS-688521 has an IC ₅₀ of 78 nM, representing an approximately 30-fold decrease in activity relative to the human T-cell/HUVEC assay data (IC ₅₀ =2.5 nM) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	BMS-688521 (1-10 mg/kg; p.o.; BID for a three-day) is efficacious in a mouse allergic eosinophilic lung inflammation model ^[1] . BMS-688521 (5 mg/kg; p.o.) treatment shows the C _{max} , T _{max} , AUC, F values are 0.32 μM, 1.0 μM, 1.5 μM h, and 50%,

respectively^[1].

BMS-688521 (1 mg/kg; i.v.) treatment shows the T_{1/2}, MRT, CL and Vss values are 1.6 hours, 1.7 hours, 50 mL/min/kg, and 5.1 L/kg, respectively in BALB/c mice^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c female mice, 6-8 week of age (OVA Lung Inflammation in Mice) ^[1]
Dosage:	1, 3, and 10 mg/kg
Administration:	p.o.; BID for a three-day
Result:	Significant inhibition of eosinophil accumulation was seen at a dose of 1 mg/kg BID, with dose-dependent inhibition at 3 mg/kg and 10 mg/kg.

REFERENCES

[1]. Watterson SH, et al. Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)nicotinic acid (BMS-688521). J Med Chem. 2010 May 13;53(9):3814-30.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA